Status: Not yet recruiting
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Participants needed: 500
Trial details
Phase: Phase 3Age: 42-89Biological sex: AllType: InterventionalSponsor: Sinovac Life Sciences Co., Ltd.Updated: May 18, 2026Locations: 1
Eligibility criteria
Health infants aged approximately 2 months (42 to 89 days) [+3]
Previous vaccination of any licensed or investigational pneumococcal vaccine, or... [+17]